MultiCell Technologies Files U.S. Patent Applicati
Post# of 94264
Posted On: 11/13/2013 8:20:04 AM
MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of MCT-485, a Noncoding miRNA for Cancer Treatment
WOONSOCKET, R.I., Nov. 13, 2013 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a second U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma. MCT-485 is currently being evaluated in animal models of hepatocellular carcinoma.
This invention addresses the need to direct the powerful biological effect of miRNAs such as MCT-485 towards tumor cells and away from normal tissues. This patent application describes compositions and methods that target populations of cancerous cells which have an enhanced capability to mediate the process of relapse, progression and metastasis. Not all cancer cells have a tumor initiating capability; this U.S. patent application describes compositions and methods that target cancer by delivering a biologically active, cytotoxic payload of miRNA to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells, and to kill those cells without killing cells not directly involved in the process of relapse, progression and metastasis of cancer.
Hepatocellular carcinoma is the most common form of primary liver cancer, and is a leading cause of cancer death worldwide. Over 1 million cases of hepatocellular carcinoma are reported annually. Current approaches for treatment of hepatocellular carcinoma are of limited efficacy. MCT-485, possessing both oncolytic and immune activating properties, could be superior to doxorubicin, cisplatin and other currently marketed therapies by providing a more robust activation of immunity, and a more global and longer lasting anti-tumor effect.
About MCT-485
MultiCell Technologies' MCT-485 is a noncoding double stranded micro RNA (miRNA), and the first of a family of prospective cancer therapeutics. MultiCell owns rights to several issued U.S. and foreign patents and patent applications related to MCT-485 and other miRNAs.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease and cancer. For more information about MultiCell Technologies, please visit http://www.multicelltech.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". MultiCell bases these forward- looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2012, and all of MultiCell's quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
SOURCE MultiCell Technologies, Inc.
Copyright 2013 PR Newswire
WOONSOCKET, R.I., Nov. 13, 2013 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a second U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma. MCT-485 is currently being evaluated in animal models of hepatocellular carcinoma.
This invention addresses the need to direct the powerful biological effect of miRNAs such as MCT-485 towards tumor cells and away from normal tissues. This patent application describes compositions and methods that target populations of cancerous cells which have an enhanced capability to mediate the process of relapse, progression and metastasis. Not all cancer cells have a tumor initiating capability; this U.S. patent application describes compositions and methods that target cancer by delivering a biologically active, cytotoxic payload of miRNA to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells, and to kill those cells without killing cells not directly involved in the process of relapse, progression and metastasis of cancer.
Hepatocellular carcinoma is the most common form of primary liver cancer, and is a leading cause of cancer death worldwide. Over 1 million cases of hepatocellular carcinoma are reported annually. Current approaches for treatment of hepatocellular carcinoma are of limited efficacy. MCT-485, possessing both oncolytic and immune activating properties, could be superior to doxorubicin, cisplatin and other currently marketed therapies by providing a more robust activation of immunity, and a more global and longer lasting anti-tumor effect.
About MCT-485
MultiCell Technologies' MCT-485 is a noncoding double stranded micro RNA (miRNA), and the first of a family of prospective cancer therapeutics. MultiCell owns rights to several issued U.S. and foreign patents and patent applications related to MCT-485 and other miRNAs.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease and cancer. For more information about MultiCell Technologies, please visit http://www.multicelltech.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". MultiCell bases these forward- looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2012, and all of MultiCell's quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
SOURCE MultiCell Technologies, Inc.
Copyright 2013 PR Newswire
(0)
(0)